Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
ID: ALA5220881
Max Phase: Preclinical
Molecular Formula: C24H28N4O3S2
Molecular Weight: 484.65
Associated Items:
ID: ALA5220881
Max Phase: Preclinical
Molecular Formula: C24H28N4O3S2
Molecular Weight: 484.65
Associated Items:
Canonical SMILES: CNCCCNS(=O)(=O)c1ccc(-c2ccc(CSc3nc4c(c(=O)[nH]3)CCC4)cc2)cc1
Standard InChI: InChI=1S/C24H28N4O3S2/c1-25-14-3-15-26-33(30,31)20-12-10-19(11-13-20)18-8-6-17(7-9-18)16-32-24-27-22-5-2-4-21(22)23(29)28-24/h6-13,25-26H,2-5,14-16H2,1H3,(H,27,28,29)
Standard InChI Key: JTUCBCNWROIZHI-UHFFFAOYSA-N
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
Molecule Type: | Topical: No | First In Class: No | Black Box: No |
Chirality: No | Availability: No | Prodrug: No |
MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
---|
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
Molecular Weight: 484.65 | Molecular Weight (Monoisotopic): 484.1603 | AlogP: 3.11 | #Rotatable Bonds: 10 |
Polar Surface Area: 103.95 | Molecular Species: BASE | HBA: 6 | HBD: 3 |
#RO5 Violations: 0 | HBA (Lipinski): 7 | HBD (Lipinski): 3 | #RO5 Violations (Lipinski): 0 |
CX Acidic pKa: 7.65 | CX Basic pKa: 10.50 | CX LogP: 2.21 | CX LogD: 1.80 |
Aromatic Rings: 3 | Heavy Atoms: 33 | QED Weighted: 0.23 | Np Likeness Score: -1.45 |
1. Fuerst R, Choi JY, Knapinska AM, Cameron MD, Ruiz C, Delmas A, Sundrud MS, Fields GB, Roush WR.. (2022) Development of a putative Zn2+-chelating but highly selective MMP-13 inhibitor., 76 [PMID:36202189] [10.1016/j.bmcl.2022.129014] |
Source(1):